Q-omics provides the consensus-scored RPS10-NUDT3 profile across patient tissues and cancer cell-line models. RPS10-NUDT3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS10-NUDT3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RPS10-NUDT3 RNA expression shows 14,010 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where RPS10-NUDT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS10-NUDT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS10-NUDT3 survival associations across molecular data types. RPS10-NUDT3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS10-NUDT3 RNA expression–survival associations across cancer types. High RPS10-NUDT3 expression shows unfavorable associations in KIRP, ACC, SCLC and BRCA, but favorable associations in LGG and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS10-NUDT3 RNA expression.
This table summarizes RPS10-NUDT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS10-NUDT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS10-NUDT3 shows higher tumor expression in HNSC, LUSC, LUAD, BRCA, COAD and CHOL. The HNSC box plot shows higher RPS10-NUDT3 RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p = .012).
This table shows molecular features associated with RPS10-NUDT3 in patient tissues and cancer cell lines. In patient samples, RPS10-NUDT3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS10-NUDT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
